What happens when human health, animal health, and entrepreneurial drug development intersect?
In this episode of Fractals: Life Science Conversations, Bracken CEO Colin Miller is joined by Senior Partners Graham Lumsden, BVM&S, Dip.M., MRCVS, and Jonathan Larkin, PhD, to discuss osteoarthritis innovation, One Medicine, and the collaborative pathways that can move novel therapies forward.
Together, they discuss:
Why osteoarthritis remains a major unmet need in both human and animal health
How disease-modifying approaches could shift treatment beyond pain management
The promise of bispecific antibody development in addressing both pain and cartilage degeneration
How animal health studies can help inform human development programs, and vice versa
Why human expertise, networks, and scientific judgment remain essential in the age of AI
Tune in to Fractals on your preferred podcast platform, and reach out to Bracken to learn how we help life science teams connect strategy, science, and execution across development.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Bracken Group. Innehållet i podden är skapat av The Bracken Group och inte av,
eller tillsammans med, Poddtoppen.
